ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. According to IMS Health, the overall market for this product was approximately $39 million in 2014.
Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, "This acquisition further expands our near-term generic pipeline. We intend to re-launch the product within the next 12 months. We are excited that this transaction further extends the ANI-Teva relationship."
ANI has forty-seven generic drug products under development addressing a total annual market size of approximately $3.0 billion, based on data from IMS Health.
Research from second pig heart transplant provides new directions for xenotransplantation